Herceptin subcutaneous is not being reviewed by CHMP this month -- not on calendar.
Kadacyla is being reviewed, which is a herceptin combination drug. That drug is very toxic and comes with a black box warning in the U.S. when it was passed by the FDA earlier this year.
I think we are waiting on HYQvia European Commission confirmation of CHMP validation back in March. I think the Mab Thera competitor failure is probably too bad for patients but good for Roche and likely Halozyme.